TY  - JOUR
U1  - Zeitschriftenartikel, wissenschaftlich - begutachtet (reviewed)
A1  - Berger, Anne Katrin
A1  - Lücke, Stephan
A1  - Abel, Ulrich
A1  - Haag, Georg Martin
A1  - Grüllich, Carsten
A1  - Stange, Annika
A1  - Dietrich, Mareike
A1  - Apostolidis, Leonidas
A1  - Freitag, Angelika
A1  - Trierweiler, Claudia
A1  - Gall, Carl von
A1  - Ose, Jennifer
A1  - Giesel, Frederik
A1  - Weber, Tim Frederik
A1  - Lordick, Florian
A1  - Haberkorn, Uwe
A1  - Jäger, Dirk
T1  - Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial
JF  - British Journal of Cancer
N2  - Background: To assess the predictive value of early metabolic response (ΔSUV) after short-term treatment with first-line cetuximab in patients (pts) with RAS-wt metastatic colorectal cancer (mCRC).

Methods: In this prospective phase II study, RAS-wt mCRC pts received a single-agent cetuximab run-in therapy of 2 weeks. ΔSUV was assessed with FDG-PET/CT on days 0 and 14. Early clinical response (ECR) was evaluated with CT on day 56 after treatment with FOLFIRI-cetuximab. Primary endpoint was the predictive significance of ΔSUV for ECR. Secondary endpoints were PFS (progression free survival), OS and the influence of ΔSUV on survival.

Results: Forty pts were enroled and 33 pts were evaluable for the primary endpoint. The CT response rate was 57.6%. For responders, ΔSUV was significantly higher (p = 0.0092). A significant association of ΔSUV with ECR was found (p = 0.02). Median PFS was 11.7 months and median OS was 33.5 months with a 1-year survival rate of 87.9%. ΔSUV was found to significantly impact the hazard for OS (p = 0.045).

Conclusions: We demonstrate that cetuximab induces metabolic responses in mCRC pts. The study endpoint was met with the ΔSUV discriminating between responders and non-responders. However, these data should be validated in larger patient cohorts.
KW  - Cancer imaging
KW  - Colorectal cancer
KW  - Dickdarmkrebs
KW  - Bildgebendes Verfahren
Y1  - 2018
UN  - https://nbn-resolving.org/urn:nbn:de:bsz:960-opus4-31699
SN  - 1532-1827
SS  - 1532-1827
U6  - https://doi.org/10.25968/opus-3169
DO  - https://doi.org/10.25968/opus-3169
VL  - 119
SP  - 170
EP  - 175
ER  -